• Patients with a diagnosis of AML relapse after allogeneic hematopoietic stem cell transplantation.

• Adequate organ function.

• Be able to understand and sign informed consent.

• Age 18 to 60 years old.

• Serum pregnancy test for females of childbearing potential that is negative within one week prior to initiation of first dose of treatment. Female patients of childbearing potential and sexually active males must agree to use a highly effective method of contraception throughout the study and for at least 90 days after the last dose of assigned treatment.

• ECOG performance status ≤ 1.

• Known HLA-matched donor without contraindications to donate.

• Life expectancy \> 3 months.